UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 2, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TOTAL VOTING RIGHTS
TOTAL NUMBER OF VOTING RIGHTS AND SHARE CAPITAL IN NOVO NORDISK A/S AS OF 31
MARCH 2008.
In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure
Obligations, Novo Nordisk is required to publish the total number of voting
rights and the size of the share capital in Novo Nordisk as per the end of the
month where changes have occurred.
Referring to Stock Exchange Announcement no 15/2008 dated 12 March 2008
announcing the result of the ordinary Annual General Meeting, please find below
a statement regarding the total number of voting rights and share capital in
Novo Nordisk as per 31 March 2008. The adoption of agenda item 6.5.1 at the
Annual General Meeting on 12 March 2008 means that following the Annual General
Meeting each B share of DKK 1.00 (the present denomination of Novo Nordisk's
shares) will carry 100 votes and each A share of DKK 1.00 will carry 1,000
votes. The voting ratio between the A and B shares has not been affected by the
change.
NUMBER OF SHARES (NOMINAL VALUE NOMINAL VALUE (DKK) NUMBER OF VOTES
DKK 1)
A SHARES 107,487,200 107,487,200 107,487,200,000
B SHARES 539,472,800 539,472,800 53,947,280,000
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 18 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: April 2, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer